En Chang
Deyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Expert opinion on drug safety
Published: February 06, 2025
Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Frontiers in pharmacology
Published: November 22, 2024
Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database.
Journal: Expert opinion on drug safety
Published: July 30, 2024
Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Expert opinion on drug safety
Published: May 03, 2024
The short- and mid-term efficacy and safety of elagolix in the management of pain associated with endometriosis: A systematic review and meta-analysis.
Journal: Journal of gynecology obstetrics and human reproduction
Published: April 22, 2024
The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Frontiers in pharmacology
Published: February 26, 2024
Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.
Journal: Frontiers in pharmacology
Published: April 19, 2023
Effects of Antihypertensive Agents on the Clinical Outcome of Hospitalized COVID-19 Patients Concomitant with Hypertension: A Systematic Review and Meta-Analysis.
Journal: Heart & lung : the journal of critical care
Published: April 17, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026